Canadian Cannabis Co. Entourage Health Shares Spike On 8% YoY Q3 Revenue Growth, Reduced Losses
Canadian Cannabis Co. Entourage Health Shares Spike On 8% YoY Q3 Revenue Growth, Reduced Losses
Canadian cannabis producer Entourage Health Corp. (TSXV:ENTG) (OTCQX:ETRGF) (FSE: 4WE) announced on Friday its third quarter financial results for the three months ended Sept. 30, 2024.
加拿大大麻股生產商Entourage Health Corp. (tsxv:ENTG) (OTCQX:ETRGF) (FSE: 4WE) 宣佈，截至2024年9月30日的第三季度財務業績於週五公佈。
The company reported an 8% year-over-year increase to CA$9.5 million ($6.8 million) in net revenue for the period. Sequentially, net revenue increased by 2.1%
公司報告稱，在該時期，淨營業收入同比增長8%，達到950萬加元（680萬美元）。按季度計，淨營業收入增長了2.1%
George Scorsis, the company's CEO and chair, said the revenue growth is a result of a strategic shift into different markets. The move allowed the company to "diversify and tap into new opportunities," Scorsis said.
公司首席執行官兼董事長George Scorsis表示，營收增長是因爲戰略轉向不同市場。Scorsis表示，這一舉措使公司能夠「實現多元化，並開發新機遇」。
Read Also: Entourage Health Cannabis Reports 9% YoY Increase In Q1 Revenue, Positive EBITDA And 'Substantial Growth'
閱讀更多：Entourage Health大麻報告顯示，同比第一季度營業收入增長9%，業績爲正EIBTDA，『大幅增長』
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 訂閱本新聞快訊，每天免費獲取Benzinga獨家分析和大麻股行業及市場的最新資訊。如果您對業務認真，不容錯過。在這裏訂閱我們的新聞簡報。
Q3 2024 Financial Results
Q3 2024財務業績
- Gross profit was CA$2.9 million, up from CA$2.4 million in the prior year's period.
- Gross margin improved to 30%, up from 27% in the same period last year, driven by enhanced operational efficiencies and automation.
- Net loss and comprehensive loss dropped to CA$8.4 million year-over-year from nearly CA$10 million.
- EBITDA was a loss of CA$1 million, representing a 70% improvement compared to a loss of CA$3.4 million in the third quarter of fiscal 2023.
- Selling, general and administrative expenses were reduced by 32%, reflecting savings from restructuring and discontinued activities in 2023.
- 毛利潤爲290萬加元，高於前一年同期的240萬加元。
- 毛利率提高至30%，較去年同期的27%提高，得益於提高的運營效率和自動化。
- 淨虧損和綜合虧損從近CA$1000萬的去年同比下降至CA$840萬。
- EBITDA虧損達CA$100萬，相較於2023財年第三季度的CA$340萬虧損，改善了70%。
- 銷售、總務和行政費用減少了32%，反映了2023年重組和已停止業務活動的節約。
What's Next
接下來怎麼做
"With the holidays approaching, we are excited to introduce several highly anticipated products, demonstrating our commitment to delivering meaningful and timely offerings," Scorsis said. "As the cannabis industry stabilizes, our team's creativity and operational focus on optimizing the business will position us as a market leader."
"隨着節日的臨近，我們很高興推出幾款備受期待的產品，展示我們致力於提供有意義且及時的產品的承諾，"Scorsis說。"隨着大麻行業的穩定，我們團隊在優化業務方面的創造力和操作重點將使我們成爲市場領導者。"
- Cannabis Co. Entourage Health Reports 126% YoY Increase In 2023 Gross Profit, Cuts Losses Significantly
- 大麻股Entourage Health報告2023年毛利潤增長126%，大幅削減虧損
ETRGF Price Action
ETRGF價格走勢
Entourage's shares traded 18.75% higher at $0.0048 per share at the time of writing on Friday.
Entourage的股價在週五本文撰寫時每股漲高18.75%，報0.0048美元。
譯文內容由第三人軟體翻譯。
